secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2026-06-26T12:30:33+00:00
Accession:  0001140361-26-026506
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio director Scott resigns at annual meeting; stockholders approve 2M share increase in stock plan
--------------------------------------------------------------------------------

- Dr. Randal W. Scott resigned as Class I director effective June 22, 2026, upon term completion, citing no disagreement.
- Stockholders approved amending 2021 Stock Option Plan to increase reserved shares by 2,000,000.
- Elected Class I directors: Momtazee, McCormick, Valantine; all received >129M votes for.
- Non-binding advisory vote on executive compensation approved (152.9M for); 1-year frequency endorsed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036126026506/0001140361-26-026506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036126026506/ef20076710_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-026506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer